Creative Planning’s Aldeyra Therapeutics ALDX Stock Holding History

Creative Planning’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.4K	Buy	38,200 +9,329	+32%	+$16K	﹤0.01%	4071
2026 Q1	$48.8K	Sell	28,871 -5,650	-16%	-$24.8K	﹤0.01%	3986
2025 Q4	$179K	Sell	34,521 -327	-0.9%	-$1.68K	﹤0.01%	3589
2025 Q3	$182K	Buy	34,848 +22,801	+189%	+$119K	﹤0.01%	3527
2025 Q2	$46.1K	Sell	12,047 -970	-7%	-$2.51K	﹤0.01%	3530
2025 Q1	$74.8K	Buy	+13,017	New	+$76.9K	﹤0.01%	3295
2024 Q2	–	Sell	-10,686	Closed	-$34.9K	–	3070
2024 Q1	$34.9K	Buy	+10,686	New	+$35.2K	﹤0.01%	2810

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Creative Planning's ALDX Position: Q2 2026 in Review

Creative Planning increased its Aldeyra Therapeutics (ALDX) stake by 32% in Q2 2026, buying an estimated $16K and bringing the position to 38,200 shares worth $81.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4071.

Creative Planning first reported a position in ALDX in Q1 2024 and has held it in 7 quarters since. The position peaked at $182K in Q3 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Creative Planning held 38,200 shares of Aldeyra Therapeutics worth $81.4K as of Q2 2026.
Creative Planning bought 9,329 Aldeyra Therapeutics shares in Q2 2026, an estimated $16K.
Aldeyra Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #4071 holding.
Creative Planning first reported a position in Aldeyra Therapeutics in Q1 2024 and has held it in 7 quarters since.
Creative Planning's Aldeyra Therapeutics position peaked at $182K in Q3 2025.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.